Navigation Links
Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
Date:8/7/2012

related clinical trials, as compared to the same period in 2011, when three trials were being planned.  This was also offset by an increase of $1.1 million in manufacturing costs in the six months ended June 30, 2012 associated with initiating the nine-month dog inhalation toxicity study and building drug supply for the ongoing CLEAR-108 and TARGET-NTM clinical trials.

General and administrative expenses decreased to $5.2 million in the six months ended June 30, 2012 from $6.0 million for the six months ended June 30, 2011.
The $0.8 million decrease was due largely to lower finance, legal and consulting fees incurred in the six months ended June 30, 2011 related to post Transave merger matters and the March 2011 reverse stock split transaction.

Investment income decreased to $0.7 million in the six months ended June 30, 2012 from $1.0 million in the six months ended June 30, 2011. The decrease is a result of the lower overall average cash and short-term investments balance for the current quarter as compared to the quarter ended June 30, 2011.

As of June 30, 2012, Insmed had total cash, cash equivalents, short-term investments, and certificate of deposits on hand totalling $75.2 million, consisting of $73.1 million in cash and short-term investments and $2.1 million in a certificate of deposit, as compared to $78.4 million of cash on hand as of December 31, 2011.  The $3.2 million decrease in total cash was due primarily to the funding of operations, consisting primarily of research and development activities, totalling $12.9 million, which was primarily offset by the net $9.7 million of funding in June 2012 under the term loan with Hercules Technology Growth Capital.

Conference CallTo participate in today's live conference call, please dial 800-299-7089 (U.S. callers) or 617-801-9714 (international), and provide passcode 17092264.  A live webcast of the call will also be available at

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
2. Insmed Incorporated Provides Corporate Update
3. Organogenesis Announces Annual College Scholarship Award Winner
4. Bion Announces Approval of New Canadian Patent
5. PDL BioPharma Announces Second Quarter 2012 Financial Results
6. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
7. Accuray Announces First CyberKnife System in South America
8. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. AMRI Announces Second Quarter 2012 Results
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Technology Applications International Corporation (the ... wholly-owned subsidiary Renuell Int,l, Inc. has signed an additional ... Administration ("NASA") at the Johnson Space Center in ... photos: tapplic.com/houstonphotos/ Charles ... pleased to announce our latest, exclusive agreement with NASA. ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... , September 2, 2014 Culot ... research and lab management services  BioData, producer ... is pleased to announce the appointment of Louis ... recently served as VP Marketing and Business Development at ... research and clinical applications. Previously, Culot worked ...
(Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, February 9, Shire plc ... has received Paragraph IV Notice letters from Barr Laboratories, ... February 2009 respectively,advising in each case of the filing ... version of 500mg, 750mg and 1gm FOSRENOL(R),(lanthanum carbonate). , ...
... 9 Cell Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) management,s presentation at the ... Eastern will be,webcast live with slides at http://www.celltherapeutics.com . , ... Waldorf-Astoria,Hotel, and will also be available for replay after the presentation. , , ... BIO CEO & ...
... Clinics of Excellence, LLC, the nation,s only physician-driven ... its 62nd comprehensive Evidence-Based Treatment Protocol covering 11 ... 4th Annual Community Oncology Conference today. "Our 200+ ... to launch the protocols across its network in ...
Cached Biology Technology:Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan 2Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol 2
(Date:9/2/2014)... which counts with the participation of the University of ... that took place in the Iberian Peninsula around the ... of atmospheric dust coming from the Sahara increased. The ... in an Alpine lake in Sierra Nevada (Granada) , ... , is based on the sedimentation of atmospheric dust ...
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... birds, that migrate by night tend to fly faster ... their destinations. This seasonal difference in flight speed is ... flights, says researcher Cecilia Nilsson of Lund University in ... . , Nilsson, in a group led by ... over three years the speed by which birds flew ...
Breaking Biology News(10 mins):Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2What you eat and not just the number of calories, is a significant factor in diabetes risk 2Migrating birds sprint in spring, but take things easy in autumn 2
... Georgia Tech City and Regional Planning study on climate ... Science and Technology , shows that "smart growth" combined ... cities, carbon dioxide (CO2) emissions the principal driver ... According to Brian Stone, associate professor of City and ...
... out one gene that contributes to insulin resistance appears ... with obesity, researchers say. Cardiovascular disease is the ... Georgia researchers trying to understand why have knocked out ... mice that get diabetes. "Even before you have ...
... COLUMBIA, Mo. More than 20 million tons of plastic ... new University of Missouri study suggest that some of the ... renewable plastic made from plants. Reducing the carbon footprint and ... also provide an additional cash crop for farmers. "Making ...
Cached Biology News:Reducing CO2 through technology and smart growth 2Decreasing insulin resistance prevents obesity-related cardiovascular damage 2Decreasing insulin resistance prevents obesity-related cardiovascular damage 3'Green' plastics could help reduce carbon footprint 2
... Human Cytokeratin TYPE II Reacts with ... Including epidermal cell keratin of 86 and ... 67kD. Broad keratin reactivity is found on ... Immunogen: Human epidermal cells ...
... Detection System is intended for use in ... by an in-house validated in vitro nucleic ... interest. • The ... hybridization capture assay designed to detect amplified ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Polymerase (RNA) II (DNA directed) polypeptide L...
Biology Products: